These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37908718)

  • 1. Universal theranostic CRISPR/Cas13a RNA-editing system for glioma.
    Wu Y; Wang Y; Zhou J; Wang J; Zhan Q; Wang Q; Yang E; Jin W; Tong F; Zhao J; Hong B; Liu J; Kang C
    Theranostics; 2023; 13(15):5305-5321. PubMed ID: 37908718
    [No Abstract]   [Full Text] [Related]  

  • 2. Specific High-Sensitivity Enzymatic Molecular Detection System Termed RPA-Based CRISPR-Cas13a for Duck Tembusu Virus Diagnostics.
    He D; Liu G; Yang J; Jiang X; Wang H; Fan Y; Gong S; Wei F; Diao Y; Tang Y
    Bioconjug Chem; 2022 Jun; 33(6):1232-1240. PubMed ID: 35586918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Fidelity and Rapid Quantification of miRNA Combining crRNA Programmability and CRISPR/Cas13a trans-Cleavage Activity.
    Shan Y; Zhou X; Huang R; Xing D
    Anal Chem; 2019 Apr; 91(8):5278-5285. PubMed ID: 30873832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CRISPR-Cas13a Gene-Editing System Induces Collateral Cleavage of RNA in Glioma Cells.
    Wang Q; Liu X; Zhou J; Yang C; Wang G; Tan Y; Wu Y; Zhang S; Yi K; Kang C
    Adv Sci (Weinh); 2019 Oct; 6(20):1901299. PubMed ID: 31637166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hierarchical self-uncloaking CRISPR-Cas13a-customized RNA nanococoons for spatial-controlled genome editing and precise cancer therapy.
    Fan N; Bian X; Li M; Chen J; Wu H; Peng Q; Bai H; Cheng W; Kong L; Ding S; Li S; Cheng W
    Sci Adv; 2022 May; 8(20):eabn7382. PubMed ID: 35584220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CRISPR-Cas13a Gemini System for noncontiguous target RNA activation.
    Zhao H; Sheng Y; Zhang T; Zhou S; Zhu Y; Qian F; Liu M; Xu W; Zhang D; Hu J
    Nat Commun; 2024 Apr; 15(1):2901. PubMed ID: 38575571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precise editing of FGFR3-TACC3 fusion genes with CRISPR-Cas13a in glioblastoma.
    Wu Y; Jin W; Wang Q; Zhou J; Wang Y; Tan Y; Cui X; Tong F; Yang E; Wang J; Kang C
    Mol Ther; 2021 Nov; 29(11):3305-3318. PubMed ID: 34274537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Foldback-crRNA-Enhanced CRISPR/Cas13a System (FCECas13a) Enables Direct Detection of Ultrashort sncRNA.
    Chen Y; Zhang Y; Luo S; Yang X; Liu C; Zhang Q; Liu Y; Zhang X
    Anal Chem; 2023 Oct; 95(42):15606-15613. PubMed ID: 37824705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rapid and efficient platform for antiviral crRNA screening using CRISPR-Cas13a-based nucleic acid detection.
    Yang L; Zhang Y; Yi W; Dong X; Niu M; Song Y; Han Y; Li H; Sun Y
    Front Immunol; 2023; 14():1116230. PubMed ID: 37228594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a.
    Liu L; Li X; Ma J; Li Z; You L; Wang J; Wang M; Zhang X; Wang Y
    Cell; 2017 Aug; 170(4):714-726.e10. PubMed ID: 28757251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
    Zhang Z; Wang Q; Liu Q; Zheng Y; Zheng C; Yi K; Zhao Y; Gu Y; Wang Y; Wang C; Zhao X; Shi L; Kang C; Liu Y
    Adv Mater; 2019 Dec; 31(51):e1905751. PubMed ID: 31709671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo growth inhibition of human cervical cancer cells via human papillomavirus E6/E7 mRNAs' cleavage by CRISPR/Cas13a system.
    Chen Y; Jiang H; Wang T; He D; Tian R; Cui Z; Tian X; Gao Q; Ma X; Yang J; Wu J; Tan S; Xu H; Tang X; Wang Y; Yu Z; Han H; Das BC; Severinov K; Hitzeroth II; Debata PR; Xu W; Fan W; Jin Z; Cao C; Yu M; Xie W; Huang Z; Hu Z; You Z
    Antiviral Res; 2020 Jun; 178():104794. PubMed ID: 32298665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in application of CRISPR-Cas13a system.
    Zhang Y; Li S; Li R; Qiu X; Fan T; Wang B; Zhang B; Zhang L
    Front Cell Infect Microbiol; 2024; 14():1291557. PubMed ID: 38524179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes.
    East-Seletsky A; O'Connell MR; Burstein D; Knott GJ; Doudna JA
    Mol Cell; 2017 May; 66(3):373-383.e3. PubMed ID: 28475872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment.
    Zhao X; Liu L; Lang J; Cheng K; Wang Y; Li X; Shi J; Wang Y; Nie G
    Cancer Lett; 2018 Sep; 431():171-181. PubMed ID: 29870774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programming the
    Liu X; Kang X; Lei C; Ren W; Liu C
    Anal Chem; 2022 Mar; 94(9):3987-3996. PubMed ID: 35193353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetrahedron supported CRISPR/Cas13a cleavage for electrochemical detection of circular RNA in bladder cancer.
    Cheng L; Yang F; Zhao Y; Liu Z; Yao X; Zhang J
    Biosens Bioelectron; 2023 Feb; 222():114982. PubMed ID: 36493719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas13a system: A novel tool for molecular diagnostics.
    Zhao L; Qiu M; Li X; Yang J; Li J
    Front Microbiol; 2022; 13():1060947. PubMed ID: 36569102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas13a based bacterial detection platform: Sensing pathogen Staphylococcus aureus in food samples.
    Zhou J; Yin L; Dong Y; Peng L; Liu G; Man S; Ma L
    Anal Chim Acta; 2020 Aug; 1127():225-233. PubMed ID: 32800128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multifunction Lipid-Based CRISPR-Cas13a Genetic Circuit Delivery System for Bladder Cancer Gene Therapy.
    Fan J; Liu Y; Liu L; Huang Y; Li X; Huang W
    ACS Synth Biol; 2020 Feb; 9(2):343-355. PubMed ID: 31891494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.